Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F ₂ -Isoprostane Formation in Hypercholesterolemic Subjects

This publication has 24 references indexed in Scilit:

• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
  Published by Elsevier ,2002
• Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy
  Journal of Clinical Investigation, 2001
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001
• Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients
  New England Journal of Medicine, 2000
• Isoprostanes: Formation, Analysis and Use As Indices of Lipid Peroxidation in Vivo
  Journal of Biological Chemistry, 1999
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL
  Atherosclerosis, 1997
• Increase in Circulating Products of Lipid Peroxidation (F₂-Isoprostanes) in Smokers — Smoking as a Cause of Oxidative Damage
  New England Journal of Medicine, 1995
• Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation.
  Journal of Clinical Investigation, 1994
• Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients
  Metabolism, 1991